The benefits and risks of abciximab, eptifibatide, or tirofiban during PCI: Class effects or do they differ?
Author:
Publisher
Wiley
Subject
Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/ccd.21954/fullpdf
Reference7 articles.
1. Guidelines for percutaneous coronary interventions;Silber;Eur Heart J,2005
2. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;American College of Cardiology, American Heart Association Task Force on Practice Guidelines;Catheter Cardiovasc Interv,2008
3. ACC/AHA 2007 guidelines for the management of patents with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Anderson;J Am Coll Cardiol,2007
4. A pericardial bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point;Ndrepepa;J Am Coll Cardiol,2008
5. One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the randomized early discharge after transradial stenting of coronary arteries (EASY) study;Bertrand;Am Heart J,2008
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route;ISRN Vascular Medicine;2011-07-09
2. Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention;Journal of Cardiovascular Medicine;2011-01
3. GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin;The Open Cardiovascular Medicine Journal;2010-07-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3